Sugi Predict

Sugi Predict / Compounds / SCHEMBL935142

SCHEMBL935142

SCHEMBL935142

Clc1ccc(-c2cccs2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 1/20 0.57
▸ PPARG P37231 1/20 0.50
▸ PPARA Q07869 1/20 0.50
▸ KCNH2 Q12809 1/20 0.50
▸ CYP17A1 P05093 1/20 0.50
▸ CYP11B1 P15538 1/20 0.50
▸ CYP11B2 P19099 1/20 0.50
▸ CYP2E1 P05181 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2A6 P11509 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2B6 P20813 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9686298 0.98 LTA4H (0.55) LTA4HPPARGPPARAKCNH2CYP17A1
Hydrogen Sulfide SCHEMBL29031294 0.98 LTA4H (0.55) LTA4HPPARGPPARAKCNH2CYP17A1
Thiophene SCHEMBL27748650 0.92 LTA4H (0.50) LTA4HPPARGPPARAKCNH2CYP17A1
SCHEMBL8005625 0.88 PPARG (0.53) LTA4HPPARGPPARAKCNH2CYP17A1
SCHEMBL27961788 0.88 KCNH2 (0.50) LTA4HPPARGPPARAKCNH2CYP17A1
SCHEMBL338810 0.87 LTA4H (0.70) LTA4HKCNH2CYP17A1CYP11B1CYP11B2
SCHEMBL10471761 0.86 DPP4 (0.49) LTA4HPPARGPPARAKCNH2CYP17A1
SCHEMBL7455134 0.85 LTA4H (0.67) LTA4HKCNH2CYP17A1CYP11B1CYP11B2
SCHEMBL1464252 0.82 — —
SCHEMBL155874 0.80 KCNH2 (0.50) LTA4HKCNH2CYP17A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118344244-A Preparation method of deuterated compound based on alkyl alcohol 大连理工大学 2024-07-16 — — CN claimed
EP-3356387-B1 ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS UNIV MONASH (AU) 2024-06-26 — — EP claimed
CN-114790179-B Sulfur-containing 2,4, 5-trisubstituted oxazole compound and preparation method and application thereof 山东理工大学 2024-05-07 — — CN claimed
CN-117586304-A Aryl phosphonate and aryl thiophosphonate compound and preparation method thereof 烟台大学 2024-02-23 — — CN claimed
CN-115028580-B Synthesis method of chemiluminescent reagent APS-5 for immunoassay 北京礼为科技有限公司 2024-02-23 — — CN claimed
CN-117486854-A One-pot method for preparing 2, 5-diaryl substituted thiophene 浙江大学 2024-02-02 — — CN claimed
CN-117326996-A Preparation method of perfluoroalkenyl aryl sulfide 西安近代化学研究所 2024-01-02 — — CN claimed
CN-117326994-A Preparation method of perfluoroalkyl aryl sulfide 西安近代化学研究所 2024-01-02 — — CN claimed
CN-115010691-B Fluorescent probe and preparation method and application thereof 山西大学 2023-12-26 — — CN claimed
CN-116949823-A Antistatic colorful reflective cloth reflective coating and preparation method thereof 夜视丽新材料股份有限公司 2023-10-27 — — CN claimed
CN-114213325-B Preparation method and application of 10-methyl-9, 10-acridine dihydride-9-thiocarboxylic acid-4-chlorophenyl ester 北京富盛嘉华医药科技有限公司 2023-06-23 — — CN claimed
CN-115608361-A Catalyst for reductive amination and preparation method and application thereof 厦门大学 2023-01-17 — — CN claimed
EP-2928470-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Siga Technologies, Inc. (US) 2015-10-14 — — EP claimed
WO-2014089378-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2014-06-12 — — WO claimed
US-20100004236-A1 PHOSPHODIESTERASE 4 INHIBITORS TEHIM ASHOK 2010-01-07 — — US claimed
US-20080139583-A1 PHOSPHODIESTERASE 4 INHIBITORS TEHIM ASHOK 2008-06-12 — — US claimed
US-7332486-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2008-02-19 — — US claimed
US-20070093510-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-26 — — US claimed
EP-1529049-A2 DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2005-05-11 — — EP claimed
WO-2004014913-A2 DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-02-19 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093510-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE3B, PDE3A LTA4H 220/4885PPARG 2143/4885PPARA 3021/4885
US-20080139583-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE3A LTA4H 220/4885PPARG 2143/4885PPARA 3021/4885
US-20100004236-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE3A LTA4H 220/4885PPARG 2143/4885PPARA 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.